Neumora Stock

neumoratx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $612.4MM

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing neuroscience drugs.

Register To Buy and Sell Shares

For more details on financing and valuation for Neumora, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Neumora’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Neumora.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

SoftBank-backed Neumora seeks $2.74 billion valuation in US IPO
Neumora Therapeutics, backed by Amgen (AMGN.O) and Japan's SoftBank (9984.T), is seeking a valuation of up to $2.74 billion in its U.S. initial public offering, as the biopharmaceutical company looks to ride a revival in stock market listings.
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high failure rate that has plagued neuroscience drug development for decades.
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.